Goldman Sachs Downgrades Intellia Therapeutics (NTLA) to Neutral, 'A quieter 2024 catalyst path'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NASDAQ: NTLA) from Buy to Neutral with a price target of $32.00.The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
